Olomoucine
Olomoucine is a purine derivative that inhibits CDKs and exhibits anti-inflammatory, neuroprotective, and anticancer activities. In macrophages, olomoucine decreases levels of NO and iNOS and suppresses activation of NF-κB. In leukemia cells, olomoucine alters cell cycle progression and inhibits proliferation. Additionally, this compound prevents cathepsin L translocation and the induction of autophagy in neurons, protecting against 6-OHDA-induced toxicity.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18950795
| Cas No. |
101622-51-9 |
|---|---|
| Purity |
≥98% |
| Formula |
C15H18N6O |
| Formula Wt. |
298.34 |
| Chemical Name |
6-Benylamino-2-(2-hydroxyethylamino)-9-methyl- purine |
| IUPAC Name |
2-[[6-(benzylamino)-9-methylpurin-2-yl]amino]ethanol |
| Synonym |
2-(Hydroxyethylamino)-6-benzylamino-9-methylpurine |
| Melting Point |
120-130°C |
| Solubility |
Soluble in DMSO or methanol. |
Wandl S, Wesierska-Gadek J. Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells? Ann N Y Acad Sci. 2009 Aug;1171:242-9. PMID: 19723061.
Fei XF, Qin ZH, Xiang B, et al. Olomoucine inhibits cathepsin L nuclear translocation, activates autophagy and attenuates toxicity of 6-hydroxydopamine. Brain Res. 2009 Apr 6;1264:85-97. PMID: 19368812.
